- 1 Title: Association of coffee consumption in metabolic syndrome: a cross-sectional and
- 2 Mendelian randomization study in UK Biobank
- 3 Tommy Hon Ting Wong ^{1,2}, Shan Luo ², Shiu Lun Au Yeung ², Jimmy Chun Yu Louie ^{1,3}
- 5 Affiliations:

15

19

- 6 1. School of Biological Sciences, Faculty of Science, The University of Hong Kong
- 7 2. School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong
- 8 3. Department of Nursing and Allied Health, School of Health Sciences, Swinburne University
- 9 of Technology, Melbourne, Australia
- 10 Corresponding author: Dr. Jimmy Chun Yu Louie
- 11 Address: Department of Nursing and Allied Health, School of Health Sciences, Swinburne
- 12 University of Technology, Melbourne, Australia
- 13 Email: jimmylouie@swin.edu.au
- 14 Tel: +61 3 9214 3504
- 16 **Funding information:** This study was supported by an internal grant from the Faculty of
- 17 Science, The University of Hong Kong.
- 18 **Conflict of interest:** None declared.
- 20 Abstract: 246
- 21 Main text: 3,051

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

Abstract Objective: To investigate the associations between coffee consumption and metabolic syndrome and its component conditions, as well as the effect of using milk, sugar, and artificial sweetener on these associations. **Research Design and Methods**: The cross-sectional analysis included 351,805 participants from the UK Biobank. Coffee consumption data was obtained using food frequency questionnaire and 24-hour recall and metabolic syndrome was ascertained based on blood biochemistry results and self-reported medication use. Odds ratios were calculated using multivariable logistic regression adjusted for lifestyle and socioeconomic factors, with verification using two-sample Mendelian randomization. Results: Coffee consumption up to 2 cups per day was inversely associated with metabolic syndrome (1 cup/day, OR: 0.88, 95% CI: 0.85, 0.92; 2 cups/day, OR: 0.90, 95% CI: 0.86, 0.93) while associations at higher intakes were near null. Mendelian randomization did not support a causal association between coffee intake and metabolic syndrome. Both self-reported and genetically predicted high coffee consumption (4 cups per day or more) were associated with central obesity. The inverse association between coffee consumption and metabolic syndrome was more profound among drinkers of ground coffee than those of instant coffee. Results were similar when stratified by the use of milk and sugar, yet the use of artificial sweetener with coffee was positively associated with metabolic syndrome and all component conditions. **Conclusions**: Coffee consumption likely increase the risk of central obesity but unlikely impact risk of metabolic syndrome. The possible health effect of using artificial sweetener with coffee warrant investigations in future studies.

- 45 Keywords: coffee, metabolic syndrome, Mendelian randomization, milk, sugar, artificial
- 46 sweetener

Introduction

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

Metabolic syndrome is a condition that involves the co-occurrence of multiple metabolic abnormalities, including high fasting blood glucose level, dyslipidemia, high blood pressure, and central obesity (1). Patients meeting the criteria of metabolic syndrome had higher risks of developing type 2 diabetes (2) and cardiovascular diseases (3). Given metabolic syndrome was estimated to be affecting 20 – 30% of the global population (4-7) and is a known risk factor for type 2 diabetes (2) and cardiovascular diseases (3), identifying modifiable factors contributing to increased risk of metabolic syndrome would be of great public health interest. A recent systematic review of cross-sectional studies suggested an inverse relationship between coffee consumption and metabolic syndrome (8). Possible mechanisms may include an improvement in energy balance which was contributed by caffeine intake (9), as well as antioxidative and anti-inflammatory effects associated with polyphenols in coffee (10). However, our recent meta-analysis (8) found that coffee consumption was not longitudinally associated with metabolic syndrome. These are also consistent with randomized controlled trials (RCTs) showing habitual coffee consumption did not affect blood glucose and lipid levels (11; 12), which indirectly suggest previous observational studies may be confounded by sociodemographic factors or reverse causation. Nevertheless, it remains possible that the effect of coffee with metabolic syndrome may differ by coffee subtypes or how the coffee was being prepared (e.g. the use of milk and sweetener). The primary aim of this study is to assess the cross-sectional association of overall coffee consumption in metabolic syndrome and its components (i.e., high fasting blood glucose, high

triglycerides, central obesity, high blood pressure, and low high-density-lipoprotein-cholesterol (HDL-cholesterol) using a large population-based study. We also conducted a Mendelian randomization study, which used genetic variants allocated at conception and hence less vulnerable to confounding, to verify the observational association (13). The secondary aims were to investigate the association of coffee consumption in metabolic syndrome differed by coffee types and the use of milk, sugar, and artificial sweetener.

Research Design and Methods

The UK Biobank

The UK Biobank is a large-scale prospective cohort aiming to improve the understanding of the prevention, diagnosis, and treatment of a wide range of common and life-threatening diseases in middle to old-aged people. The design and the protocol of this project has been previously published (14; 15). In brief, approximately 500,000 participants with 40 – 69 years of age living in the United Kingdom were recruited during 2006 – 2010. Data regarding demographics, socioeconomic status, health, and diet were collected in 22 assessment centers across the United Kingdom and blood samples were also taken for biochemical analyses. All UK Biobank participants were genotyped using either the Affymetrix UK BiLEVE Axiom or Affymetrix UK Biobank Axiom array. The UK Biobank project was approved by the National Information Governance Board for Health and Social Care and the NHS North West Multicenter Research Ethics Committee (reference number: 11/NW/0382). Written consent was obtained from all participants.

Habitual coffee intake

Participants were asked "How many cups of coffee do you drink each day (include decaffeinated coffee)?" and they were prompted to enter their average amount of consumption over the last year in positive integers in a food frequency questionnaire (FFQ). Participants were also asked to select the type of coffee that they used to drink at that time and available responses included "decaffeinated coffee", "instant coffee", "ground coffee (include espresso, filter etc.)", and "other type of coffee". Participants recruited during 2009-2010 also filled in a detailed 24-hour recall dietary questionnaire in addition to the FFQ. In the 24-hr recall questionnaire they were asked "Did you drink any coffee yesterday?" with a "Yes/No" option. For those who selected "Yes" they were further asked for their consumption (in cups or mugs) of different types of coffee on the previous day. Available options for coffee types included instant coffee, filtered coffee, cappuccino, latte, espresso, decaffeinated coffee, and other coffee types. Participants also reported whether they added milk to instant and filtered coffee, as well as sugar or artificial sweetener (in teaspoon) when drinking coffee in general.

Outcomes

The primary outcome was metabolic syndrome, which was defined by the International Diabetes Federation in 2009 (1) as having any 3 of the following: high fasting glucose, high triglycerides, central obesity, high blood pressure, and low HDL-cholesterol (secondary outcomes). The detailed criteria for each condition was listed in **Supplemental Table 1**. Waist circumference was measured in cm using a measurement tape (SECA). Blood pressure (mmHg) was measured twice using the IntelliSense blood pressure monitor model HEM-907XL (Omron) for each participant and the average of the two measurements were used in this study. Serum levels of

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

glucose (mmol/L), triglycerides (mmol/L), and HDL-cholesterol (mmol/L) were all measured using the Beckman Coulter AU5800 platform. Medications for treating abnormal levels of glucose, lipids, and blood pressure were self-reported and the corresponding medication code were shown in Supplemental Table 2. The details of case and control ascertainment and handling of missing data was stated in **Supplemental Information**. Potential confounders We considered age, sex, socioeconomic position (Townsend Deprivation index, and highest qualification obtained), lifestyle factors (smoking status, alcohol intake frequency, physical activity, and intakes of fruit, vegetable, and tea) as possible confounders. Details of measurement were provided in the **Supplemental Information**. Genetic predictors of coffee consumption Genetic predictors of coffee consumption, i.e., single nucleotide polymorphisms (SNPs), were retrieved from a genome-wide association study (GWAS) of predominantly European ancestry in the Coffee and Caffeine Genetics Consortium (CCGC) (16). These included (i) coffee consumption in cups per day among coffee drinkers (phenotype 1, n = 129,488) and (ii) no/low versus high coffee consumption (phenotype 2, n = 65,842). Only independent SNPs ($r^2 < 0.001$) that were genome-wide significant ($p < 5 \times 10^{-8}$) in the trans-ethnic meta-analysis were selected. Genetic associations of the outcomes The genetic associations between the SNPs identified for cups of coffee consumed (phenotype 1) and being a coffee drinker (phenotype 2) with metabolic syndromes and its components were

obtained from the UK Biobank participants of European ancestry. The genetic associations of outcomes were obtained using multivariable logistic regression, adjusted for age, sex, top 20 principal components, genotype array, and assessment center. Participants with poor quality genotyping (missing rate > 0.01), ≥ 10 putative third-degree relatives, with sex chromosome aneuploidy, with a mismatch between genetic sex and reported sex, and those with a mismatch in reported ethnicity and genetic ethnicity were excluded. Up to 360,903 participants provided data for the genetic associations of outcomes.

Statistical analyses

148 Cross sectional analyses

We assessed the cross-sectional associations of coffee consumption in metabolic syndrome and its components using multivariable logistic regressions with zero consumers as the reference group. Effect estimates were adjusted for potential confounders (age, sex, Townsend deprivation index, highest qualification attained, smoking status, alcohol intake frequency, physical activity level, fruit intake, vegetable intake, and tea consumption). We also included coffee type as a covariate when analyzing data collected from 24-hour recalls. To investigate the association between using milk, sugar, and artificial sweetener with coffee and all outcomes, we stratified the main analyses by these factors whenever possible. Stratification by milk use was carried out for instant and filtered coffee, while stratification by use of sugar and artificial sweetener was also carried out for all coffee types except espresso due to a lack of cases.

Mendelian randomization analysis

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

We calculated the R^2 (only phenotype 1) and F statistics of the instruments as an indicator of instrument strength based on equations used in a previous Mendelian randomization study (17), where a higher F statistic indicated lower evidence for weak instrument bias. Effect alleles of all instruments were aligned to the coffee consumption-increasing allele. We assessed the causal association of coffee consumption in metabolic syndrome and its component conditions using inverse variance weighted (IVW) with multiplicative random effect models. The IVW estimator assumes balanced horizontal pleiotropy (18) and high heterogeneity among instrument-specific Wald Ratios based on Cochran's Q test may imply the inclusion of invalid instruments. To assess the robustness of our findings, we also conducted a range of sensitivity analyses which were based on different assumptions. The MR-Egger estimator allows for overall directional pleiotropic effects by assuming the instrument strength is independent of the direct effect (InSIDE assumption). An MR-Egger intercept with a p-value < 0.05 reflects the presence of horizontal pleiotropic effect (18). The weighted median method assumes at least 50% of the weight come from valid SNPs (19). Since smoking status and alcohol consumption were wellrecognized confounding factors in the associations between coffee consumption and various health outcomes (20) and genetic predictors of coffee consumption were found to be associated with both traits as well (20) we conducted multivariable MR to obtain effect estimates adjusted for alcohol consumption and liability to smoking initiation. Details regarding the multivariable Mendelian randomization analysis was provided in the **Supplemental Information**.

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

To correct for multiple testing, the p-value threshold for statistical significance for all analyses was set at 0.0083 (0.05 divided by 6 outcomes). Results Participant characteristics Participants who had withdrawn, were not British, without coffee consumption data, and without data on any confounding variables were excluded from all analyses. Those with missing individual outcome variables were excluded from the corresponding analyses. The detail exclusion flowchart was shown in **Figure 1**. The characteristics of all included participants (n =351,805) were shown in **Table 1**. Participants who consumed coffee were more likely to be male, more likely to be current smoker, consumed alcohol more frequently, had higher education attainment, and drank less tea. Association of coffee consumption and metabolic syndrome, and its components Figure 2 shows the association between consuming cups of coffee per day and metabolic syndrome amongst 142,594 participants, after controlling for potential confounders. Participants consuming up to 3 cups of coffee per day were less likely to have metabolic syndrome when compared with coffee abstainers (<1 cup per day, OR: 0.91, 95% CI: 0.87, 0.96; 1 cup per day, OR: 0.88, 95% CI: 0.85, 0.92; 2 cups per day, OR: 0.90, 95% CI: 0.86, 0.93; 3 cups per day, OR: 0.94, 95% CI: 0.90, 0.99). However, consuming 4 cups of coffee or more per day was potentially associated with higher odds of having metabolic syndrome (4 cups per day, OR: 1.03, 95% CI: 0.98, 1.08; 5 cups per day, OR: 1.06, 95% CI: 0.99, 1.12; 6 cups per day, OR: 1.05, 95% CI: 0.99, 1.11). Coffee consumption was also positively associated with high fasting glucose and high

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

triglycerides, but inversely associated with having high blood pressure and low HDL-cholesterol (**Figure 2**). The association between coffee consumption and central obesity was J-shaped. Using Mendelian randomization (8 instruments for cups of coffee consumed: R^2 : 0.4%. F statistics: 56.1, and the range of F statistics for the 3 instruments for liability to high coffee consumption: 44.4 - 100.0) (Supplemental Table 3), we did not identify any association of these two coffee phenotypes with risk of metabolic syndrome using IVW (Figure 3). Although the instruments were heterogenous based on Cochran's Q, there was no strong evidence for overall horizontal pleiotropy based on MR-Egger intercept (Supplemental Tables 4 and 5). Adjusting for the liability to smoke initiation and alcohol consumption did not lead to material changes in the results (Supplemental Tables 6 - 9). However, both coffee phenotypes were associated with higher risk of central obesity, with directionally consistent findings from the sensitivity analyses (Figure 3). After adjusting for genetic liabilities to smoking initiation and alcohol consumption, results of both phenotypes were similar to those of the univariate MR. There was suggestive evidence that both phenotypes were associated with higher risk of high fasting glucose, but not high triglycerides, high blood pressure and low HDL-cholesterol (Figure **3**). Association of coffee subtypes, the use of sugar/milk, in metabolic syndrome and its components The directions of associations observed among drinkers of instant coffee, ground coffee, and decaffeinated coffee mostly aligned with those of the main results with a few exceptions (**Figure** 2). For instance, null associations were observed between instant coffee intake with metabolic syndrome and high blood pressure, as well as between decaffeinated coffee intake and low HDL-

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

cholesterol. Latte and cappuccino intake was inversely associated with metabolic syndrome and high blood pressure only, while all associations for espresso intake were near null (Supplemental Figures 1-2). Results of analysis stratified by use of milk, sugar, and artificial sweetener were shown in **Supplemental Figures 1 – 4.** Stratifying by milk use did not affect any of the associations. Sugar use was inversely associated with high fasting glucose and central obesity among drinkers of instant coffee but not other coffee types. Artificial sweetener use was positively associated with all outcomes among instant coffee consumers. Similarly, filtered coffee intake with artificial sweetener was positively associated with all outcomes except high fasting glucose and high triglycerides. Avoidance of artificial sweetener was inversely associated with metabolic syndrome, central obesity, and low HDLcholesterol among filtered coffee drinkers, as well as metabolic syndrome and high blood pressure among latte and cappuccino drinkers. **Discussion** In this large population-based study, we found habitual coffee consumption at 1-3 cups per day was associated with lower risk of metabolic syndrome. However, these associations were not replicated using Mendelian randomization, implying possible confounding in the observational analyses. We also observed that only ground and decaffeinated coffee intakes were inversely associated with metabolic syndrome, while a null association was observed among instant coffee drinkers. Moreover, we showed for the first time in Europeans that while milk and sugar use did not substantially affect the association between coffee intake and metabolic syndrome, the use of artificial sweetener was positively associated with metabolic syndrome and all component conditions among both instant and filtered coffee drinkers.

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

Our study was consistent with a previous smaller Danish study which also showed an inverse observational association of coffee consumption in metabolic syndrome but not in Mendelian randomization (21). As such, the inverse association observed in previous studies (22; 23) could possibly be due to residual confounding, such as variation in diet quality (24). However, we also observed a positive association of coffee consumption in central obesity in the observational and genetic analyses, a finding that was in line with a previous one-sample Mendelian randomization study (25) that observed a positive association between coffee consumption and obesity, but inconsistent with previous observational studies (26). The bioactive components in coffee unlikely explained this association, since caffeine consumption may enhance lipolysis and foodinduced thermogenesis (27), while evidence regarding the effect of polyphenols found in coffee on preventing obesity have been inconsistent (28). Furthermore, a recent longitudinal study observed a mild association between habitual coffee consumption and waist circumference reduction (29). One possible cause behind our findings could be psychological stress, which is a well-known factor of obesity (30). Evidence from observational studies supported a positive association between caffeine intake and psychological stress (31; 32). Although cortisol, which was an established marker for psychological stress, was found to be causally unrelated to waistto-hip ratio and body-mass-index (33), the authors acknowledged that genetically predicted cortisol may not be a direct reflection of stress, which would induce other biological responses other than cortisol elevation, such as the release of inflammatory cytokines (34). Further studies

are warranted to investigate if psychological stress is in the same causal pathway as coffee intake and central obesity.

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

One novel aspect of this study was to explore the role of additives in the relation of coffee consumption in metabolic syndrome, where we showed the use of artificial sweeteners were associated with metabolic syndrome and all component conditions. There were reports linking artificial sweetener use with increased caloric intake, worsened glycemic control, long-term weight gain, and metabolic syndrome (35). One possible mechanism behind our finding is that since sweet taste is treated by the brain as a signal of incoming caloric content, the lack of energy in the artificial sweetener would weaken this perception, leading to dysregulation in nutrient signaling and subsequent homeostasis (36). Another proposed mechanism is that artificial sweetener intake could alter the microbiota composition in human gut, thereby inducing glucose intolerance (37). Nonetheless, while the evidence regarding the effect of artificial sweetener use on weight management and glycemic control was highly mixed (38; 39), our findings could be also explained by reverse causation where they used artificial sweeteners because of their poor metabolic health. Further longitudinal studies are needed to determine if the use of sugar and artificial sweeteners augments the association between coffee consumption and metabolic syndrome.

Strengths of this study include large sample size and the use of different approaches to interrogate the role of coffee consumption in metabolic syndrome, as well as the role of additives. Nevertheless, several limitations of this analysis should be acknowledged. First, the definitions of metabolic syndrome used in this study required fasting measurement of biomarkers, thus a

portion of the participants had to be excluded from the analyses of certain outcomes and the results may possibly be affected by selection bias. Second, some analyses that were stratified by use of sugar and artificial sweetener were left with very few cases, thus the statistical power of such tests could be limited. Third, although we corrected for possible horizontal pleiotropy via alcohol and tobacco use using multivariable Mendelian randomization, the genetic instruments used in this analysis were also associated with tea consumption, as shown in a previous study (20), and hence may be biased by horizontal pleiotropy although the findings were generally consistent in other sensitivity analyses which were more robust to violation via horizontal pleiotropy, such as MR-Egger. Fourth, the use of a dichotomized exposure variable (phenotype 2) could possibly violate the instrumental variable assumption of MR (40). Finally, results from this study may not be generalizable to populations of non-European ancestry because the data used in this study were collected from participants of European origin only.

To conclude, low-to-moderate coffee intake (1-3 cups per day) was associated with lower risk of metabolic syndrome in cross-sectional analyses, but such associations were not supported by Mendelian randomization. However, high coffee consumption may contribute to higher risk of central obesity. Our findings also highlighted the variation in results due to coffee types and use of sugar and artificial sweeteners. Nonetheless, the findings should be verified in future longitudinal studies with data in coffee consumption and use of coffee additives, while the causal relationship between coffee intake and metabolic health outcomes should be verified in future Mendelian randomization studies involving more genetic instruments for coffee consumption.

Data availability

The data used in this study can be requested via application to UK Biobank (https://www.ukbiobank.ac.uk).

Acknowledgement

The present study was conducted under UK Biobank application number 44407.

Authors' contributions: JCYL and TWHT designed research; SL, AYSL, and JCYL provided essential materials; TWHT analyzed the data, performed statistical analysis, and drafted the paper; all authors critically evaluated and amended the manuscript. TWHT and JCYL had primary responsibility for the final content. All authors read and approved the final manuscript.

Reference

- 329 1. Alberti KGMM, Eckel Robert H, Grundy Scott M, Zimmet Paul Z, Cleeman James I, Donato
- 330 Karen A, Fruchart J-C, James WPT, Loria Catherine M, Smith Sidney C: Harmonizing the
- 331 Metabolic Syndrome. Circulation 2009;120:1640-1645
- 332 2. DeBoer MD, Filipp SL, Gurka MJ: Use of a Metabolic Syndrome Severity
- 333 Z Score to Track Risk During Treatment of Prediabetes: An Analysis of
- the Diabetes Prevention Program. Diabetes Care 2018;41:2421
- 335 3. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL,
- 336 Eisenberg MJ: The Metabolic Syndrome and Cardiovascular Risk: A Systematic Review and
- 337 Meta-Analysis. Journal of the American College of Cardiology 2010;56:1113-1132
- 4. Hirode G, Wong RJ: Trends in the Prevalence of Metabolic Syndrome in the United States,
- 339 2011-2016. JAMA 2020;323:2526-2528
- 5. Tanamas SK, Magliano DJ, Lynch B, Sethi P, Willenberg L, Polkinghorne KR, Chadban S,
- Dunstan D, JE S: AusDiab 2012. The Australian Diabetes, Obesity and Lifestyle Study.
- 342 Melbourne, 2013
- 6. Scuteri A, Laurent S, Cucca F, Cockcroft J, Cunha PG, Mañas LR, Raso FUM, Muiesan ML,
- Ryliškytė L, Rietzschel E, Strait J, Vlachopoulos C, Völzke H, Lakatta EG, Nilsson PM, for the
- 345 Metabolic S, Arteries Research C: Metabolic syndrome across Europe: Different clusters of risk
- factors. European Journal of Preventive Cardiology 2015;22:486-491
- 7. Liu B, Chen G, Zhao R, Huang D, Tao L: Temporal trends in the prevalence of metabolic
- 348 syndrome among middle-aged and elderly adults from 2011 to 2015 in China: the China health
- and retirement longitudinal study (CHARLS). BMC Public Health 2021;21:1045

- 8. Wong THT, Wong CH, Zhang X, Zhou Y, Xu J, Yuen KC, Wan JMF, Louie JCY: The
- 351 Association Between Coffee Consumption and Metabolic Syndrome in Adults: A Systematic
- Review and Meta-Analysis. Advances in Nutrition 2021;12:708-721
- 9. Harpaz E, Tamir S, Weinstein A, Weinstein Y: The effect of caffeine on energy balance.
- Journal of Basic and Clinical Physiology and Pharmacology 2017;28:1-10
- 355 10. van Dam RM, Hu FB, Willett WC: Coffee, Caffeine, and Health. New England Journal of
- 356 Medicine 2020;383:369-378
- 357 11. Alperet DJ, Rebello SA, Khoo EY-H, Tay Z, Seah SS-Y, Tai B-C, Tai ES, Emady-Azar S,
- 358 Chou CJ, Darimont C, van Dam RM: The effect of coffee consumption on insulin sensitivity and
- 359 other biological risk factors for type 2 diabetes: a randomized placebo-controlled trial. The
- 360 American Journal of Clinical Nutrition 2020;111:448-458
- 361 12. Du Y, Lv Y, Zha W, Hong X, Luo Q: Effect of coffee consumption on dyslipidemia: A meta-
- analysis of randomized controlled trials. Nutrition, Metabolism and Cardiovascular Diseases
- 363 2020;30:2159-2170
- 364 13. Davies NM, Holmes MV, Davey Smith G: Reading Mendelian randomisation studies: a
- guide, glossary, and checklist for clinicians. BMJ 2018;362:k601
- 366 14. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott P, Green J,
- Landray M, Liu B, Matthews P, Ong G, Pell J, Silman A, Young A, Sprosen T, Peakman T,
- 368 Collins R: UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range
- of Complex Diseases of Middle and Old Age. PLOS Medicine 2015;12:e1001779
- 370 15. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A, Vukcevic D,
- Delaneau O, O'Connell J, Cortes A, Welsh S, McVean G, Leslie S, Donnelly P, Marchini J:
- 372 Genome-wide genetic data on ~500,000 UK Biobank participants. bioRxiv 2017:166298

373 16. Cornelis MC, Byrne EM, Esko T, Nalls MA, Ganna A, Paynter N, Monda KL, Amin N, 374 Fischer K, Renstrom F, Ngwa JS, Huikari V, Cavadino A, Nolte IM, Teumer A, Yu K, Marques-375 Vidal P, Rawal R, Manichaikul A, Wojczynski MK, Vink JM, Zhao JH, Burlutsky G, Lahti J, 376 Mikkilä V, Lemaitre RN, Eriksson J, Musani SK, Tanaka T, Geller F, Luan J, Hui J, Mägi R, 377 Dimitriou M, Garcia ME, Ho WK, Wright MJ, Rose LM, Magnusson PKE, Pedersen NL, 378 Couper D, Oostra BA, Hofman A, Ikram MA, Tiemeier HW, Uitterlinden AG, van Rooij FJA, 379 Barroso I, Johansson I, Xue L, Kaakinen M, Milani L, Power C, Snieder H, Stolk RP, 380 Baumeister SE, Biffar R, Gu F, Bastardot F, Kutalik Z, Jacobs DR, Forouhi NG, Mihailov E, 381 Lind L, Lindgren C, Michaëlsson K, Morris A, Jensen M, Khaw KT, Luben RN, Wang JJ, 382 Männistö S, Perälä MM, Kähönen M, Lehtimäki T, Viikari J, Mozaffarian D, Mukamal K, Psaty 383 BM, Döring A, Heath AC, Montgomery GW, Dahmen N, Carithers T, Tucker KL, Ferrucci L, 384 Boyd HA, Melbye M, Treur JL, Mellström D, Hottenga JJ, Prokopenko I, Tönjes A, Deloukas P, 385 Kanoni S, Lorentzon M, Houston DK, Liu Y, Danesh J, Rasheed A, Mason MA, Zonderman AB, 386 Franke L, Kristal BS, Karjalainen J, Reed DR, Westra HJ, Evans MK, Saleheen D, Harris TB, 387 Dedoussis G, Curhan G, Stumvoll M, Beilby J, Pasquale LR, Feenstra B, Bandinelli S, Ordovas 388 JM, Chan AT, Peters U, Ohlsson C, Gieger C, Martin NG, Waldenberger M, Siscovick DS, 389 Raitakari O, Eriksson JG, Mitchell P, Hunter DJ, Kraft P, Rimm EB, Boomsma DI, Borecki IB, 390 Loos RJF, Wareham NJ, Vollenweider P, Caporaso N, Grabe HJ, Neuhouser ML, Wolffenbuttel 391 BHR, Hu FB, Hyppönen E, Järvelin MR, Cupples LA, Franks PW, Ridker PM, van Duijn CM, 392 Heiss G, Metspalu A, North KE, Ingelsson E, Nettleton JA, van Dam RM, Chasman DI, The C, 393 Caffeine Genetics C, International Parkinson's Disease Genomics C, North American Brain 394 Expression C, Consortium UKBE: Genome-wide meta-analysis identifies six novel loci 395 associated with habitual coffee consumption. Molecular Psychiatry 2015;20:647-656

- 396 17. Au Yeung SL, Borges MC, Lawlor DA, Schooling CM: Impact of lung function on
- 397 cardiovascular diseases and cardiovascular risk factors: a two sample bidirectional Mendelian
- 398 randomisation study. Thorax 2021:thoraxjnl-2020-215600
- 399 18. Bowden J, Del Greco M F, Minelli C, Davey Smith G, Sheehan N, Thompson J: A
- 400 framework for the investigation of pleiotropy in two-sample summary data Mendelian
- 401 randomization. Statistics in Medicine 2017;36:1783-1802
- 402 19. Bowden J, Davey Smith G, Haycock PC, Burgess S: Consistent Estimation in Mendelian
- 403 Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genetic
- 404 Epidemiology 2016;40:304-314
- 405 20. Taylor AE, Davey Smith G, Munafò MR: Associations of coffee genetic risk scores with
- 406 consumption of coffee, tea and other beverages in the UK Biobank. Addiction 2018;113:148-157
- 407 21. Nordestgaard AT, Thomsen M, Nordestgaard BG: Coffee intake and risk of obesity,
- 408 metabolic syndrome and type 2 diabetes: a Mendelian randomization study. International Journal
- 409 of Epidemiology 2015;44:551-565
- 410 22. Grosso G, Stepaniak U, Micek A, Topor-Mądry R, Pikhart H, Szafraniec K, Pająk A:
- 411 Association of daily coffee and tea consumption and metabolic syndrome: results from the Polish
- arm of the HAPIEE study. European Journal of Nutrition 2015;54:1129-1137
- 413 23. Micek A, Grosso G, Polak M, Kozakiewicz K, Tykarski A, Puch Walczak A, Drygas W,
- 414 Kwaśniewska M, Pajak A: Association between tea and coffee consumption and prevalence of
- 415 metabolic syndrome in Poland results from the WOBASZ II study (2013–2014). International
- Journal of Food Sciences and Nutrition 2018;69:358-368

- 417 24. Wong THT, Sui Z, Rangan A, Louie JCY: Discrepancy in socioeconomic status does not
- 418 fully explain the variation in diet quality between consumers of different coffee types. European
- 419 Journal of Nutrition 2018;57:2123-2131
- 420 25. Nicolopoulos K, Mulugeta A, Zhou A, Hyppönen E: Association between habitual coffee
- 421 consumption and multiple disease outcomes: A Mendelian randomisation phenome-wide
- 422 association study in the UK Biobank. Clinical Nutrition 2020;39:3467-3476
- 423 26. Lee A, Lim W, Kim S, Khil H, Cheon E, An S, Hong S, Lee DH, Kang S-S, Oh H, Keum N,
- 424 Hsieh C-C: Coffee Intake and Obesity: A Meta-Analysis. Nutrients 2019;11
- 425 27. Acheson KJ, Zahorska-Markiewicz B, Pittet P, Anantharaman K, Jéquier E: Caffeine and
- 426 coffee: their influence on metabolic rate and substrate utilization in normal weight and obese
- individuals. The American Journal of Clinical Nutrition 1980;33:989-997
- 428 28. Tajik N, Tajik M, Mack I, Enck P: The potential effects of chlorogenic acid, the main
- 429 phenolic components in coffee, on health: a comprehensive review of the literature. European
- 430 Journal of Nutrition 2017;56:2215-2244
- 431 29. Larsen SC, Mikkelsen ML, Frederiksen P, Heitmann BL: Habitual coffee consumption and
- 432 changes in measures of adiposity: a comprehensive study of longitudinal associations.
- 433 International Journal of Obesity 2018;42:880-886
- 434 30. Tomiyama AJ: Stress and Obesity. Annual Review of Psychology 2019;70:703-718
- 435 31. Magalhães R, Picó-Pérez M, Esteves M, Vieira R, Castanho TC, Amorim L, Sousa M,
- Coelho A, Fernandes HM, Cabral J, Moreira PS, Sousa N: Habitual coffee drinkers display a
- distinct pattern of brain functional connectivity. Molecular Psychiatry 2021;26:6589-6598
- 438 32. Zunhammer M, Eichhammer P, Busch V: Sleep Quality during Exam Stress: The Role of
- 439 Alcohol, Caffeine and Nicotine. PLOS ONE 2014;9:e109490

- 440 33. Kwok MK, Kawachi I, Rehkopf D, Schooling CM: The role of cortisol in ischemic heart
- disease, ischemic stroke, type 2 diabetes, and cardiovascular disease risk factors: a bi-directional
- 442 Mendelian randomization study. BMC Medicine 2020;18:363
- 34. Ippoliti F, Canitano N, Businaro R: Stress and Obesity as Risk Factors in Cardiovascular
- Diseases: A Neuroimmune Perspective. Journal of Neuroimmune Pharmacology 2013;8:212-226
- 35. Azad MB, Abou-Setta AM, Chauhan BF, Rabbani R, Lys J, Copstein L, Mann A, Jeyaraman
- 446 MM, Reid AE, Fiander M, MacKay DS, McGavock J, Wicklow B, Zarychanski R: Nonnutritive
- sweeteners and cardiometabolic health: a systematic review and meta-analysis of randomized
- 448 controlled trials and prospective cohort studies. Canadian Medical Association Journal
- 449 2017;189:E929
- 450 36. Swithers SE: Artificial sweeteners produce the counterintuitive effect of inducing metabolic
- derangements. Trends in Endocrinology & Metabolism 2013;24:431-441
- 452 37. Suez J, Korem T, Zeevi D, Zilberman-Schapira G, Thaiss CA, Maza O, Israeli D, Zmora N,
- 453 Gilad S, Weinberger A, Kuperman Y, Harmelin A, Kolodkin-Gal I, Shapiro H, Halpern Z, Segal
- E, Elinav E: Artificial sweeteners induce glucose intolerance by altering the gut microbiota.
- 455 Nature 2014;514:181-186
- 456 38. Kim Y, Keogh JB, Clifton PM: Non-nutritive Sweeteners and Glycaemic Control. Current
- 457 Atherosclerosis Reports 2019;21:49
- 458 39. Pearlman M, Obert J, Casey L: The Association Between Artificial Sweeteners and Obesity.
- 459 Current Gastroenterology Reports 2017;19:64
- 460 40. Burgess S, Labrecque JA: Mendelian randomization with a binary exposure variable:
- 461 interpretation and presentation of causal estimates. European Journal of Epidemiology
- 462 2018;33:947-952

Table 1 – characteristics of participants included in cross-sectional analysis (n = 351,805)

Variables	Coffee consumption (cups/day)							
	0	<1	1	2	3	4	5	6 or more
Participants, n	72860	24309	71116	67516	44629	30940	18260	22175
Age, years	55.5 (8.2)	56.4 (7.9)	57.3 (8.0)	57.2 (7.9)	57.0 (7.9)	56.6 (7.9)	56.0 (8.0)	55.6 (8.0)
Male, %	43.5	47.0	45.2	48.1	49.9	52.2	54.2	55.6
Smoking status, %								
Never	57.6	58.3	57.4	55.7	54.3	50.9	47.2	39.9
Previous	33.2	34.2	35.7	36.1	36.6	37.4	37.2	35.9
Current	9.2	7.5	6.9	8.2	9.0	11.7	15.6	24.1
Alcohol consumption frequ	uency, %							
Monthly or less	37.7	27.1	24.9	21.8	21.6	22.7	25.8	32.3
Weekly	46.0	52.7	53.1	53.2	52.5	52.4	51.1	46.9
Daily	16.3	20.2	22.0	25.0	25.8	24.8	23.1	20.8
Fruit intake, tbsp	3.0 (2.5)	3.1 (2.4)	3.2 (2.5)	3.2 (2.5)	3.0 (2.4)	2.9 (2.3)	2.8 (2.4)	2.7 (2.6)
Vegetable intake, tbsp	4.7 (3.3)	4.7 (3.0)	4.9 (3.0)	4.9 (3.0)	4.8 (3.0)	4.8 (3.1)	4.7 (3.1)	4.8 (3.5)
Tea intake, cups/day	4.7 (3.3)	4.6 (2.8)	4.0 (2.5)	3.3 (2.4)	2.6 (2.2)	2.2 (2.3)	1.8 (2.5)	1.9 (3.3)
IPAQ category, %								
Low	20.0	19.3	17.0	17.1	18.3	19.2	21.4	22.3
Moderate	39.0	42.0	41.6	42.1	42.1	41.3	39.6	38.1
High	41.0	38.7	41.4	40.8	39.6	39.5	39.0	39.6
Highest qualification obtain	ned, %							
Below GCSE	26.1	18.2	21.3	18.6	18.1	20.2	20.6	23.9
GCSE	24.7	21.8	21.5	21.3	20.9	22.0	22.8	24.1
Advanced level	7.7	8.4	7.6	7.7	7.7	7.4	7.3	7.6
Degree holder	41.6	51.6	49.7	52.4	53.3	50.4	49.4	44.5

Values are mean (SD) for age and percentages for count variables. Coffee consumption was analyzed as a categorical variable. GCSE, general certificate of secondary education. IPAQ, International Physical Activity Questionnaire.

Figure 1 – Participant exclusion flowchart for the cross-sectional analysis.






Figure 2 – Associations between overall coffee consumption, as well as stratified by coffee types, and metabolic syndrome, high fasting glucose, high triglycerides, central obesity, high blood pressure, and low HDL-cholesterol.



Error bars are 95% CI. All data used were from the baseline food frequency questionnaire. All effect estimates were adjusted for age, sex, smoking status, alcohol consumption frequency, highest qualification obtained, vegetable intake, fruit intake, tea intake, and physical activity level.

Figure 3 – Results of MR analysis between coffee intake and metabolic syndrome, high fasting glucose, high triglycerides, central obesity, high blood pressure, and low HDL-cholesterol.



Error bars are 95% CI. Effect estimates of MVMR are adjusted for alcohol consumption and liability to smoke initiation. Coffee consumption was measured among coffee consumers only. For liability to high coffee consumption, high coffee consumption was defined as 4 cups or more per day.